Compare VCEL & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VCEL | NVAX |
|---|---|---|
| Founded | 1989 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | 1996 | 1996 |
| Metric | VCEL | NVAX |
|---|---|---|
| Price | $46.23 | $8.88 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 9 |
| Target Price | ★ $57.75 | $11.33 |
| AVG Volume (30 Days) | 598.5K | ★ 4.4M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 60.00 | ★ 309.76 |
| EPS | N/A | ★ N/A |
| Revenue | $276,259,000.00 | ★ $1,123,479,000.00 |
| Revenue This Year | $19.40 | N/A |
| Revenue Next Year | $18.24 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 16.45 | ★ 64.69 |
| 52 Week Low | $28.95 | $6.20 |
| 52 Week High | $43.57 | $11.85 |
| Indicator | VCEL | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 81.81 | 46.20 |
| Support Level | $32.47 | $8.89 |
| Resistance Level | N/A | $9.02 |
| Average True Range (ATR) | 1.61 | 0.60 |
| MACD | 0.70 | -0.08 |
| Stochastic Oscillator | 96.76 | 36.52 |
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.